Business Wire

FORE Biotherapeutics Presents Phase 1/2a Plixorafenib Data Demonstrating Prolonged Duration of Effect in BRAF Altered Thyroid Cancers at American Thyroid Association® 2025 ...

PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today presented new ...
Seeking Alpha

Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer

New approval based on TADPOLE trial showing overall response rate (ORR) of 47% and median progression-free survival (mPFS) of 20.1 months for Tafinlar + Mekinist compared to 11% ORR and 7.4 months ...
News Medical

Research discovers fibronectin's role in BRAF-mutant thyroid cancer resistance

New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, PhD, could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF gene ...
Targeted Oncology

Dr Nabil Saba on Optimizing Anaplastic Thyroid Cancer Outcomes

Dr Nabil Saba emphasizes that while systemic therapy has revolutionized the treatment of anaplastic thyroid cancer (ATC), ...
EurekAlert!

New directions in targeting the multifaceted BRAF in cancer

“Here we discuss the diverse forms of BRAF alterations found in human cancers and the strategies to inhibit them in patients harboring cancers of distinct origins.” “Here we discuss the diverse forms ...
Cure Today

Braftovi Combo Delays Progression in BRAF-Mutant mCRC

Braftovi plus Erbitux and FOLFIRI improved progression-free survival in untreated BRAF V600E metastatic colorectal cancer in the phase 3 BREAKWATER trial. A targeted treatment that includes Braftovi ...